In a report which went to Tuesday's meeting of the city council's development management committee, planners said the benefits of the plan outweighed any negative impact on the city's heritage assets.
The FDA initially declined to approve it, asking in March 2010 for more information about the drug's prescribing label and the companies' risk-management plan to ensure the drug's benefits outweigh its risks.
It is, however, believed to include some role for the federal Office of Personnel Management, which oversees the Federal Employee Health BenefitsPlan, the group of private health insurance plans that covers some 9 million federal workers and their dependents.